| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aromatase inhibitors, cardiovascular medications, and patient outcomes
|
Luo, Peng
|
|
|
26 |
2 |
p. e74
|
artikel
|
| 2 |
Aromatase inhibitors, cardiovascular medications, and patient outcomes – Authors' reply
|
Lund, Marie
|
|
|
26 |
2 |
p. e75
|
artikel
|
| 3 |
Bullous Wells syndrome in a patient with occult nasopharyngeal carcinoma
|
Li, Mengmeng
|
|
|
26 |
2 |
p. e122
|
artikel
|
| 4 |
Cancer incidence associated with PFAS contamination of drinking water in the USA
|
Gruber, Karl
|
|
|
26 |
2 |
p. 160
|
artikel
|
| 5 |
CHIPOR: gaps in recurrent ovarian cancer management
|
Toyran, Atahan
|
|
|
26 |
2 |
p. e76
|
artikel
|
| 6 |
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
|
Ruan, Dan-Yun
|
|
|
26 |
2 |
p. 227-238
|
artikel
|
| 7 |
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials
|
Gyawali, Bishal
|
|
|
26 |
2 |
p. e80-e89
|
artikel
|
| 8 |
Correction to Lancet Oncol 2019; 20: 1750–59
|
|
|
|
26 |
2 |
p. e77
|
artikel
|
| 9 |
Correction to Lancet Oncol 2021; 22: 1081–92
|
|
|
|
26 |
2 |
p. e77
|
artikel
|
| 10 |
Differences in the on-label cancer indications of medicinal products between Europe and the USA
|
Perini, Martina
|
|
|
26 |
2 |
p. e103-e110
|
artikel
|
| 11 |
Expanding therapeutic options targeting claudin-18.2
|
Herbert, Katharine
|
|
|
26 |
2 |
p. 153-155
|
artikel
|
| 12 |
Fires and their smouldering health effects
|
The Lancet Oncology,
|
|
|
26 |
2 |
p. 147
|
artikel
|
| 13 |
Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study
|
Moraes, Fabio Y
|
|
|
26 |
2 |
p. 239-248
|
artikel
|
| 14 |
Hiring freezes within the NHS impact cancer care
|
Devi, Sharmila
|
|
|
26 |
2 |
p. 159
|
artikel
|
| 15 |
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
|
Wang, Michael
|
|
|
26 |
2 |
p. 200-213
|
artikel
|
| 16 |
India is boosting vaccination efforts to eradicate cervical cancer
|
Gruber, Karl
|
|
|
26 |
2 |
p. e78
|
artikel
|
| 17 |
Insights into the future of first-line advanced hepatocellular carcinoma treatment
|
Wong, Jeffrey Sum Lung
|
|
|
26 |
2 |
p. 152-153
|
artikel
|
| 18 |
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
|
Semaan, Karl
|
|
|
26 |
2 |
p. 161-164
|
artikel
|
| 19 |
Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG)
|
Eochagain, Colm Mac
|
|
|
26 |
2 |
p. e90-e102
|
artikel
|
| 20 |
Mantle cell lymphoma: is it time for risk-adapted treatment?
|
Glimelius, Ingrid
|
|
|
26 |
2 |
p. 150-152
|
artikel
|
| 21 |
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
|
Chong, Wan-Qin
|
|
|
26 |
2 |
p. 175-186
|
artikel
|
| 22 |
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study
|
Nadauld, Lincoln
|
|
|
26 |
2 |
p. 165-174
|
artikel
|
| 23 |
Rethinking metastatic brain cancer as a CNS disease
|
Fares, Jawad
|
|
|
26 |
2 |
p. e111-e121
|
artikel
|
| 24 |
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
|
Oza, Amit M
|
|
|
26 |
2 |
p. 249-264
|
artikel
|
| 25 |
Solidifying local ablation in the treatment of small-size colorectal liver metastasis
|
Stöffler, Laura
|
|
|
26 |
2 |
p. 149-150
|
artikel
|
| 26 |
Texan judge blocks US FDA changes on cigarette packaging
|
Devi, Sharmila
|
|
|
26 |
2 |
p. e79
|
artikel
|
| 27 |
Thank you to The Lancet Oncology's reviewers in 2024
|
The Lancet Oncology Editors,
|
|
|
26 |
2 |
p. e67-e73
|
artikel
|
| 28 |
The psychological impact of screening with a multicancer early detection test
|
Emery, Jon
|
|
|
26 |
2 |
p. 148-149
|
artikel
|
| 29 |
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
|
van der Lei, Susan
|
|
|
26 |
2 |
p. 187-199
|
artikel
|
| 30 |
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
|
Finn, Richard S
|
|
|
26 |
2 |
p. 214-226
|
artikel
|
| 31 |
Transforming oncology care in Latin America: artificial intelligence-driven solutions to bridge workforce gaps
|
Moraes, Fabio Y
|
|
|
26 |
2 |
p. 155-157
|
artikel
|
| 32 |
US Surgeon General calls for cancer warning labels on alcohol
|
Kirby, Tony
|
|
|
26 |
2 |
p. 158
|
artikel
|
Tijdschrift beschrijving